



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

Date: February 13th, 2019

To, The Department of Corporate Services- Listing Bombay Stock Exchange Ltd, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001	To, National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051
Scrip Code: 507789	Symbol: JAGSNPHARM

**SUB: SUBMISSION OF UN-AUDITED STANDALONE FINANCIAL RESULTS
ALONG WITH LIMITED REVIEW REPORT FOR THE QUARTER ENDED 31ST
DECEMBER, 2018.**

Dear Sir,

In terms of the provisions of Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Un-audited Standalone Financial Results for the 3rd Quarter ended 31st December, 2018 duly approved by the Board at its meeting held on 13th February, 2019.


The Limited Review on the Un-audited Standalone Financial Results for the Quarter ended 31st December, 2018 in accordance with Regulation 33 of the SEBI (Listing Obligation and Disclosure requirements) Regulation 2015 is also enclosed herewith.

Kindly take the above on record & oblige.

Thanking You,

For **JAGSONPAL PHARMACEUTICALS LIMITED**

R K Kapoor
Company Secretary cum Compliance Officer





JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office : T-210J, Shahpur Jat, New Delhi - 110 049 (INDIA)

Fax : 0091-11-26498341, 26494708, Phone : 0091-11-26494519-24

CIN No. L74899DL1978PLC009181

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31 DECEMBER, 2018

(Amount in Lakhs unless otherwise indicated)

S. No	Particulars	Quarter Ended			Nine Months		Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
I	Revenue From operations	4189.45	4412.49	3805.65	12842.34	9393.11	12660.42
II	Other Income	27.86	18.3	3.06	54.95	32.42	45.68
III	Total Income (I+II)	4217.31	4430.79	3808.71	12897.29	9425.53	12706.1
IV	EXPENSES						
	Cost of materials consumed	1290.77	990.99	596.82	3132.32	2404.92	2688.6
	Purchases of Stock-in-Trade	399.8	208.53	954.58	924.69	3072.56	3830.84
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	106.07	766.19				
				479.4	1840.63	-493.39	-408.44
	Excise Duty	0	0	0	0	7.13	7.13
	Employee benefits expense	1274.04	1264.76	1042.14	3601.22	3105.77	4187.97
	Finance costs	10.42	19.74	22.66	47.24	60.44	65.72
	Depreciation and amortization expenses	23.06	24.99	2.11	73.45	26.47	31.98
	Other expenses	898.72	934.35	940.26	2751.16	2283.43	3464.97
	Total expenses (IV)	4002.88	4209.55	4037.97	12370.71	10467.33	13868.77
V	Profit/(loss) before exceptional items and tax (I-IV)	214.43	221.24	-229.26	526.58	-1041.8	-1162.67
VI	Exceptional Items	0	0	0	0	0	0
VII	Profit/ (loss) before exceptions items and tax(V-VI)	214.43	221.24	-229.26	526.58	-1041.8	-1162.67
VIII	Tax expense	40.00	44.25	-4.56	102.43	-13.69	-7.61
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	174.43	176.99	-224.70	424.15	-1028.11	-1155.06
X	Profit/(loss) from discontinued operations	0	0	0	0	0	0
XI	Tax expenses of discontinued operations	0	0	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Profit/(loss) for the period (IX+XII)	174.43	176.99	-224.70	424.15	-1028.11	-1155.06
XIV	Other Comprehensive Income	0	0	0	0	0	0
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	174.43	176.99	-224.70	424.15	-1028.11	-1155.06
XVI	Paid-up Equity Share Capital (Face Value of Rs. 5 each)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
XVI	Earnings per equity share (for continuing operation)	0.67	0.68	-0.86	1.62	-3.92	-4.41

Note:

- 1 The Financial Result for the quarter ended 31st December 2018 were approved by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on 13 February, 2019.
- 2 The Statutory Auditors have carried out limited review of the Standalone Financial Results for the quarter ended 31st December 2018.
- 3 The investors Complaints: At the beginning of the quarter-0; received during the quarter-8; resolving during the quarter-8; closing position-0.
- 4 In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
- 5 Figures for the previous periods are re-classified/re-arranged/ re-grouped, whenever necessary.
- 6 According to the requirements of Ind AS and SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, revenue for the corresponding Nine Months ended 31-12-2017 and year ended March 31,2018 were reported inclusive of Excise Duty. The Government of India has implemented Goods and Service Tax ("gst") from July 01, 2017 replacing Excise Duty, Service Tax and various indirect taxes. AS per Ind AS 18, the revenue for the Nine Months ended 31-12-2017, is reported net of GST and is not comparable with previous reported nine months.

Date: 13 February, 2019
Place: New Delhi



By Order of the Board
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar

Rajpal Singh Kochhar
Managing Director
DIN: 00059492



LIMITED REVIEW REPORT

The Board of Directors
Jagsonpal Pharmaceuticals Limited
T-210-J, Shahpur Jat
New Delhi-110049

1. We have reviewed the Unaudited Financial Results of Jagsonpal Pharmaceuticals Limited (the "Company") for the Quarter and nine months ended 31st December, 2018 which are included in the accompanying Statement of Standalone Financial Results for the Quarter ended 31 December, 2018 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") and SEBI Circular dated July 5, 2016, which has been initialed by us for identification purposes.
2. The Statement is the responsibility of the Company's management and is also responsible to ensure that the accounting policies used in preparation of this Statement are consistent and are in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with IND AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing regulations, 2015 and SEBI circular dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Our conclusion is not qualified in respect of these matters.

Date: 13 February, 2019
Place: New Delhi

For H.L. Bansal & Co.
Firm Registration Number: 08563N
Chartered Accountants
H. L. Bansal
Proprietor
Membership Number 086990

